OTCMKTS:ZLDPF - Zealand Pharma Aktieselskabet Stock Price, News & Analysis

$21.60
0.00 (0.00 %)
(As of 08/22/2019 04:00 PM ET)
Today's Range
$21.60
Now: $21.60
$21.60
50-Day Range
$21.60
MA: $22.16
$22.60
52-Week Range
$12.1001
Now: $21.60
$22.60
VolumeN/A
Average Volume1,120 shs
Market Capitalization$664.20 million
P/E RatioN/A
Dividend YieldN/A
Beta-0.34
Zealand Pharma A/S, a biotechnology company, engages in the discovery, design, and development of peptide therapeutics-based medicines in Denmark. It has a portfolio of proprietary medicines in late-stage clinical development focusing on gastrointestinal and metabolic diseases. The company markets lixisenatide for the treatment of type 2 diabetes under the brand names of Adlyxin and Lyxumia; and a combination of lixisenatide and insulin glargine for the treatment of type 2 diabetes under the brand names of Soliqua 100/33 and Suliqua. Read More…

Industry, Sector and Symbol

Industry Private households
Sub-IndustryN/A
SectorMedical
Current SymbolOTCMKTS:ZLDPF
Previous SymbolNASDAQ:ZLDPF
CUSIPN/A
CIKN/A
Phone45-8877-3600

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$34.91 million

Profitability

Miscellaneous

Employees149
Market Cap$664.20 million
Next Earnings Date8/22/2019 (Estimated)
OptionableNot Optionable

Receive ZLDPF News and Ratings via Email

Sign-up to receive the latest news and ratings for ZLDPF and its competitors with MarketBeat's FREE daily newsletter.


Zealand Pharma Aktieselskabet (OTCMKTS:ZLDPF) Frequently Asked Questions

What is Zealand Pharma Aktieselskabet's stock symbol?

Zealand Pharma Aktieselskabet trades on the OTCMKTS under the ticker symbol "ZLDPF."

When is Zealand Pharma Aktieselskabet's next earnings date?

Zealand Pharma Aktieselskabet is scheduled to release their next quarterly earnings announcement on Thursday, August 22nd 2019. View Earnings Estimates for Zealand Pharma Aktieselskabet.

Has Zealand Pharma Aktieselskabet been receiving favorable news coverage?

News coverage about ZLDPF stock has been trending positive this week, InfoTrie Sentiment reports. The research group rates the sentiment of press coverage by analyzing more than six thousand blog and news sources in real-time. The firm ranks coverage of public companies on a scale of negative five to five, with scores nearest to five being the most favorable. Zealand Pharma Aktieselskabet earned a media sentiment score of 2.5 on InfoTrie's scale. They also assigned headlines about the company a news buzz of 6.0 out of 10, indicating that recent press coverage is somewhat likely to have an effect on the stock's share price in the near future. View News Stories for Zealand Pharma Aktieselskabet.

Who are some of Zealand Pharma Aktieselskabet's key competitors?

What other stocks do shareholders of Zealand Pharma Aktieselskabet own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Zealand Pharma Aktieselskabet investors own include ZEALAND PHARMA/S (ZEAL), Agenus (AGEN), Aduro BioTech (ADRO), Adial Pharmaceuticals (ADIL), Adobe (ADBE), Acasti Pharma (ACST), AcelRx Pharmaceuticals (ACRX), Acorda Therapeutics (ACOR), Axon Enterprise (AAXN) and GlaxoSmithKline (GSK).

Who are Zealand Pharma Aktieselskabet's key executives?

Zealand Pharma Aktieselskabet's management team includes the folowing people:
  • Mr. Mats Peter Blom M.B.A., MBA, Exec. VP & CFO (Age 54)
  • Ms. Hanne Heidenheim Bak, Sr. Project Director, R&D Operations Mang. and Employee Director (Age 66)
  • Mr. Adam Steensberg M.D., Interim CEO, Exec. VP and Chief Medical & Devel. Officer (Age 45)
  • Thierry Lanuque, Head of Fin. & Accountant
  • Dr. Andrew Parker, Exec. VP & Chief Science Officer (Age 54)

How do I buy shares of Zealand Pharma Aktieselskabet?

Shares of ZLDPF can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Zealand Pharma Aktieselskabet's stock price today?

One share of ZLDPF stock can currently be purchased for approximately $21.60.

How big of a company is Zealand Pharma Aktieselskabet?

Zealand Pharma Aktieselskabet has a market capitalization of $664.20 million and generates $34.91 million in revenue each year. Zealand Pharma Aktieselskabet employs 149 workers across the globe.View Additional Information About Zealand Pharma Aktieselskabet.

What is Zealand Pharma Aktieselskabet's official website?

The official website for Zealand Pharma Aktieselskabet is http://www.zealandpharma.com/.

How can I contact Zealand Pharma Aktieselskabet?

Zealand Pharma Aktieselskabet's mailing address is Smedeland 36 Glostrup, Copenhagen G7, 2600. The company can be reached via phone at 45-8877-3600 or via email at [email protected]


MarketBeat Community Rating for Zealand Pharma Aktieselskabet (OTCMKTS ZLDPF)

Community Ranking:  2.3 out of 5 (star star)
Outperform Votes:  61 (Vote Outperform)
Underperform Votes:  72 (Vote Underperform)
Total Votes:  133
MarketBeat's community ratings are surveys of what our community members think about Zealand Pharma Aktieselskabet and other stocks. Vote "Outperform" if you believe ZLDPF will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ZLDPF will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 8/22/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel